Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Betts

Showing results (261-270 of 389) with videos related to

Pageof 39
Sort By:
Kidney Medicine|November 7, 2022
CKD Progression and Economic Burden in Individuals With CKD Associated With Type 2 DiabetesC Daniel Mullins, Kevin M Pantalone, Keith A Betts, et al.
Advanced Drug Delivery Reviews|March 10, 2015
Delivery of therapeutic oligonucleotides with cell penetrating peptidesPrisca Boisguérin, Sébastien Deshayes, Michael J Gait, et al.
Pharmacoeconomics - Open|November 6, 2024
Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line TreatmentYan Chen, Ella X Du, Manasvi Sundar, et al.
Journal of Sports Sciences|December 15, 2020
The effects of glucose-fructose co-ingestion on repeated performance during a day of intensified rugby union training in professional academy playersAaron Hengist, Jonathan D Watkins, Harry A Smith, et al.
European Journal of Applied Physiology|June 4, 2020
The day-to-day reliability of peak fat oxidation and FAT<sub>MAX</sub>Oliver J Chrzanowski-Smith, Robert M Edinburgh, Mark P Thomas, et al.
Journal of the American Academy of Dermatology|October 11, 2017
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trialsKenneth B Gordon, Keith A Betts, Murali Sundaram, et al.
Lung Cancer (Amsterdam, Netherlands)|April 24, 2021
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancerDavid Waterhouse, Jenny Lam, Keith A Betts, et al.
Journal of Managed Care & Specialty Pharmacy|May 27, 2020
Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia AZheng-Yi Zhou, Karina Raimundo, Anisha M Patel, et al.
Future Oncology (London, England)|April 14, 2021
Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapyDavid Stenehjem, Solomon Lubinga, Keith A Betts, et al.
Current Medical Research and Opinion|October 31, 2014
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparisonJames E Signorovitch, Keith A Betts, William M Reichmann, et al.
Pageof 39

Showing results (261-270 of 389) with videos related to

Sort By:
Pageof 39
Kidney Medicine|November 7, 2022
CKD Progression and Economic Burden in Individuals With CKD Associated With Type 2 DiabetesC Daniel Mullins, Kevin M Pantalone, Keith A Betts, et al.
Advanced Drug Delivery Reviews|March 10, 2015
Delivery of therapeutic oligonucleotides with cell penetrating peptidesPrisca Boisguérin, Sébastien Deshayes, Michael J Gait, et al.
Pharmacoeconomics - Open|November 6, 2024
Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line TreatmentYan Chen, Ella X Du, Manasvi Sundar, et al.
Journal of Sports Sciences|December 15, 2020
The effects of glucose-fructose co-ingestion on repeated performance during a day of intensified rugby union training in professional academy playersAaron Hengist, Jonathan D Watkins, Harry A Smith, et al.
European Journal of Applied Physiology|June 4, 2020
The day-to-day reliability of peak fat oxidation and FAT<sub>MAX</sub>Oliver J Chrzanowski-Smith, Robert M Edinburgh, Mark P Thomas, et al.
Journal of the American Academy of Dermatology|October 11, 2017
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trialsKenneth B Gordon, Keith A Betts, Murali Sundaram, et al.
Lung Cancer (Amsterdam, Netherlands)|April 24, 2021
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancerDavid Waterhouse, Jenny Lam, Keith A Betts, et al.
Journal of Managed Care & Specialty Pharmacy|May 27, 2020
Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia AZheng-Yi Zhou, Karina Raimundo, Anisha M Patel, et al.
Future Oncology (London, England)|April 14, 2021
Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapyDavid Stenehjem, Solomon Lubinga, Keith A Betts, et al.
Current Medical Research and Opinion|October 31, 2014
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparisonJames E Signorovitch, Keith A Betts, William M Reichmann, et al.
Pageof 39